Evidence review
GLP-1, the Heart and the Kidneys: The SELECT and FLOW Trials
Semaglutide's two newest FDA indications aren't about weight loss at all — they're for reducing heart-attack, stroke and kidney-disease risk directly.
On this page
Our #1-rated provider
CoreAge Rx
AOne price at every dose, both molecules, all 50 states. The $99 and $149 figures are 12-month plans paid up front, not a monthly bill.
Check availability- Semaglutide
- $99/mo12-month prepay
- Tirzepatide
- $149/mo12-month prepay
- Coverage
- All 50 states
- Access
- Compounded
Advertising disclosure · we may earn a commission at no extra cost to you. It never changes what we write about a product — an unflattering finding on a paying provider stays in.
Also here
Care Bare Rx
COral as well as injectable routes for both molecules and a real brand Ozempic lane, with the pharmacies and prescribing physicians named — and one shared price floor covering all of it.
Check Care Bare Rx availabilityWeight loss is not the only thing semaglutide is now FDA-approved to do. Two large outcomes trials, run specifically to test cardiovascular and kidney endpoints rather than the number on the scale, led to two separate label expansions — and both matter regardless of how much weight a patient loses.
SELECT: cardiovascular risk, independent of diabetes
The SELECT trial enrolled 17,604 adults with established cardiovascular disease and overweight or obesity, but without diabetes — a population outside the traditional GLP-1 diabetes-outcomes evidence base. Over a median follow-up beyond three years, semaglutide reduced the composite rate of cardiovascular death, non-fatal heart attack, or non-fatal stroke to 6.5%, versus 8.0% on placebo1. In March 2024, the FDA approved Wegovy specifically to reduce this risk in adults with cardiovascular disease and obesity or overweight — the first weight-management drug ever approved for that purpose2.
FLOW: kidney outcomes in type 2 diabetes
The FLOW trial studied a different population: 3,533 adults with type 2 diabetes and chronic kidney disease, on top of standard care. Semaglutide reduced the risk of the trial's composite kidney and cardiovascular-death outcome, with a hazard ratio of 0.76 — a 24% relative risk reduction3. In January 2025, the FDA approved Ozempic to reduce the risk of sustained kidney function decline, kidney failure, and cardiovascular death specifically in adults with type 2 diabetes and chronic kidney disease4.
Why these are two separate approvals, not one
Ozempic and Wegovy are the same molecule under different FDA approvals to begin with — see Ozempic vs Wegovy for that distinction. SELECT and FLOW extend that split further: Wegovy's cardiovascular claim is approved for a non-diabetic population with existing heart disease, while Ozempic's kidney claim is approved for a diabetic population with chronic kidney disease. Neither trial's result transfers to the other drug's label, and neither transfers to tirzepatide, which was not the molecule studied in either trial.
What this means beyond the prescription pad
Both trials are evidence that at least one GLP-1 molecule has measurable effects on hard outcomes — death, heart attack, stroke, kidney failure — that are not fully explained by weight loss alone; both trials adjusted for and discussed effects beyond the weight change itself13. That is a meaningfully different claim than "this drug helps you lose weight," and it is part of why these two approvals specifically cite outcomes data rather than a weight-loss percentage. A third GLP-1 molecule picked up its own outcomes-based approval outside weight loss in December 2024, when Zepbound (tirzepatide) became the first drug ever FDA-approved for obstructive sleep apnea — see Zepbound and sleep apnea for the trial numbers behind that one.
Related reading
For the full molecule-level picture, see GLP-1 side effects for the safety data behind both drugs, and semaglutide vs tirzepatide for how the two GLP-1 molecules compare on the weight-loss evidence these outcomes trials build on. If you're choosing a provider with either of these conditions in mind, confirm brand-name access on the best semaglutide providers ranking rather than assuming a compounded version carries the same FDA-reviewed indication. The rest of our sourced evidence is in the research library.
Frequently asked questions
Does semaglutide reduce heart attack and stroke risk?
In the SELECT trial — 17,604 adults with cardiovascular disease and obesity or overweight but no diabetes — semaglutide reduced the composite rate of cardiovascular death, non-fatal heart attack or non-fatal stroke to 6.5%, versus 8.0% on placebo. The FDA approved Wegovy for this specific use in March 2024.
Does semaglutide help kidney disease?
In the FLOW trial — 3,533 adults with type 2 diabetes and chronic kidney disease — semaglutide reduced the risk of the trial's composite kidney and cardiovascular-death outcome by 24% (hazard ratio 0.76). The FDA approved Ozempic for this use in January 2025.
Does tirzepatide have the same heart and kidney approvals?
No. SELECT and FLOW both studied semaglutide specifically, not tirzepatide, and neither approval extends to Zepbound's label.
Are these benefits separate from weight loss?
Both trials specifically examined outcomes — death, heart attack, stroke, kidney failure — as a distinct question from the weight-loss percentage, and both discussed effects that were not fully explained by weight change alone.
References
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/37952131/
- U.S. Food and Drug Administration (2024). FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight. FDA.gov, Press Announcements. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or
- Perkovic V, Tuttle KR, Rossing P, et al. (2024). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/38785209/
- U.S. Food and Drug Administration (2025). Ozempic (semaglutide) injection — Supplemental Approval Letter, Chronic Kidney Disease Indication. Drugs@FDA. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/209637Orig1s025ltr.pdf
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.
Continue reading
GLP-1 Side Effects: What the Trials and FDA Labels Actually Show
Real numbers from the pivotal trials and FDA labels — how common nausea and diarrhea are, the boxed warnings, and when a side effect means call your provider.
ReadWegovy vs Zepbound: What the Trials — and One Head-to-Head Study — Show
Wegovy is semaglutide, Zepbound is tirzepatide. The pivotal trials, a real head-to-head study, and what each drug's own FDA label adds the other doesn't.
ReadWegovy vs Saxenda: The Randomized Trial That Compared Them Directly
Saxenda (liraglutide) came first; Wegovy (semaglutide) came later. A real randomized trial — STEP 8 — compared them directly. Here's what it found.
ReadGLP-1 Drugs for PCOS: What the Trials Actually Show
No GLP-1 drug is FDA-approved for PCOS. What the randomized trials that exist found on weight, hormones, and reproductive outcomes — and their real limits.
ReadMedicare GLP-1 Coverage: What Part D Pays Now
Why Part D excludes weight-loss drugs, what the $50 Medicare GLP-1 Bridge covers, who qualifies, and which indications your own plan already pays for.
ReadHow to Choose a GLP-1 Provider That Fits You
A six-point checklist for picking a GLP-1 telehealth provider — price, state access, molecule, speed, support and licensing — matched to your situation.
Read